Genetic Therapy Using Bone Marrow Transplantation

  • Richard E. Giles
  • Elie G. Hanania
  • Siqing Fu
  • Albert Deisseroth
Part of the Cancer Treatment and Research book series (CTAR, volume 76)


Genetic therapy often involves the use of replication-incompetent retroviral vectors that are designed to carry information into the genome of the somatic cells of the body. The strategies most frequently utilized have involved the ex vivo modification of hematopoietic cells, as shown in Table 1 [1–9]. These strategies have involved the harvesting of peripheral blood and marrow early progenitor cells, following which these cells are incubated ex vivo with the transducing vector and then reinfused into the patients after delivery of some form of preparative therapy that is designed to reduce the number of competing cells. In those cases in which correction of the genetic defect in the hematopoietic cells has provided a selective growth advantage to the hematopoietic cells, there has been no necessity for the use of preparative therapy to ensure the dominance of the genetically modified cells following transplantation. In addition, because the frequency of the genetic modification is often in the 2–10% range for retroviral vectors, and often the genetic modification confers no selective advantage on the modified cells, several investigators have initiated in vitro animal models and in vivo clinical trials in humans that are designed to test if chemotherapy resistance genes can be used to confer a selective growth advantage on the genetically modified cells to ensure that the modified cells will be retained after transduction and transplantation.


Hematopoietic Cell Acute Myelogenous Leukemia Autologous Bone Marrow Transcription Unit Familial Hypercholesterolemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Culver KW, Ram Z, Wellbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256:1550–1552, 1992.PubMedCrossRefGoogle Scholar
  2. 2.
    Wilson J: Ex vivo gene therapy of familial hypercholesterolemia. Human Gene Ther 3:179–222, 1992.CrossRefGoogle Scholar
  3. 3.
    Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ: Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207–216, 1993.PubMedCrossRefGoogle Scholar
  4. 4.
    Rill DR, Buschle M, Foreman NK, Bartholomew C, Moen RC, Santana VM, Inle JN, Brenner MK: Retro virus mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Human Gene Ther 3:129–136,1992.Google Scholar
  5. 5.
    Aebersold P, Kasid A, Rosenberg SA: Selection of Gene marked tumor infiltration lymphocytes from post treatment biopsies: A case study. Human Gene Ther 1:373–384, 1990.CrossRefGoogle Scholar
  6. 6.
    Claxton D, Suh S-P, Eilaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, Belmont J, Moore K, Talpaz M, Kantarjian H, Deisseroth A: Molecular analysis of retro viral transduction in chronic myelogenous leukemia. Human Gene Ther 2:317–321, 1991.CrossRefGoogle Scholar
  7. 7.
    Etkin M, Filaccio M, Ellerson D, Suh S-P, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Moseley AM, Reading C, Khouri I, Talpaz M, Kantarjian H, Deisseroth A: Use of cell-free retro viral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals. Human Gene Ther 3:137–145, 1992.CrossRefGoogle Scholar
  8. 8.
    Culver KW, Anderson WF, Blaese RM: Lymphocyte gene therapy. Human Gene Ther 2:107–109, 1991.CrossRefGoogle Scholar
  9. 9.
    Brenner M, Rill D, Moen R, Krance RA, Mirro J Jr., Anderson WF Ihle, JN: Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 341:85–86, 1993.PubMedCrossRefGoogle Scholar
  10. 10.
    Moore KA, Deisseroth A, Reading C, Williams DE, Belmont J: Stromal support enhances cell free retroviral vector transduction of human bone marrow long-term culture initiating cells. Blood 79:1393–1399, 1992.PubMedGoogle Scholar
  11. 11.
    Brenner MK, Rill D, Holladay MS, Heslop H, Moen R, Buschle M, Krance RA, Santara U, Anderson WF, Ihle J: Gene marking to determine whether autologous marrow infusion restores long term hemopoiesis in cancer patients. Lancet 342:1134–1137, 1993.PubMedCrossRefGoogle Scholar
  12. 12.
    Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WF, Hester J, Korbling M, Durett A, Moen R, Berenson R, Heimfeld S, Brenner M, Hamer J, Calvert L, Tibbits P, Talpaz M, Kantarjian H, Champlin R, Reading C: Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia contribute to relapse after autologous bone marrow in CML. Blood 83:3068–3076, 1994.PubMedGoogle Scholar
  13. 13.
    Kasid A, Morechi S, Aebersold P, Cornetta K, Culver K, Freeman S, Director E, Lotze MT, Blaese RM, Anderson WF, Rosenbetrg S: Human gene transfer: Characterization of human tumor infiltrating lymphocytes as vehicles for retroviral mediated gene transfer in man. Proc Natl Acad Sci USA 87:473–477, 1990.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilson J, personal communication, 1994.Google Scholar
  15. 15.
    Sorrentino BP, Brandt SJ, Bodine D, Gottesman M, Pastan I, Cline A, Nienhuis A: Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257:99–103, 1992.PubMedCrossRefGoogle Scholar
  16. 16.
    Podda S, Ward M, Himelstein A, Richardson C, dela Flor-Weiss E, Smith L, Gottesman M, Pastan I, Bank A: Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci USA 89:9676–9680, 1992.PubMedCrossRefGoogle Scholar
  17. 17.
    Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Andreeff M, Mechetner E, Roninson I, Giles R, Berenson R, Heimfeld S, Deisseroth AB: Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retro virus that contains the MDR-1 chemotherapy resistance gene. Gene Ther, In Press, 1995.Google Scholar
  18. 18.
    Hanania EG, Fu S, Roninson I, Zu Z, Gottesman MM, Deisseroth AB: Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther, In Press, 1995.Google Scholar
  19. 19.
    Hanania EG, Deisseroth AB: Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retro viral vector in a mouse gene therapy model. Cancer Gene Ther 1:21–25, 1994.PubMedGoogle Scholar
  20. 20.
    Kantarjian H, Talpaz M, Hester J, Korbling M, Liang J, Rios MB, Calvert L, Deisseroth AB: Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by conventional dose chemotherapy. J Clin Oncol 13:553–559, 1995.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Richard E. Giles
  • Elie G. Hanania
  • Siqing Fu
  • Albert Deisseroth

There are no affiliations available

Personalised recommendations